{"nct_id": "NCT90000001", "eligibility_text": "Inclusion: Participants must be 18 years or older. HbA1c <= 8.5%. Exclusion: Active infection or major surgery within the last 3 months.", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "Inclusion: Participants must be 18 years or older"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "active infection", "unit": null, "evidence_text": "Exclusion: Active infection or major surgery within the last 3 months"}, {"type": "INCLUSION", "field": "lab", "operator": "<=", "value": "HbA1c 8.5", "unit": null, "evidence_text": "HbA1c <= 8.5%"}, {"type": "EXCLUSION", "field": "procedure", "operator": "WITHIN_LAST", "value": 3, "unit": "months", "evidence_text": "Exclusion: Active infection or major surgery within the last 3 months"}]}
{"nct_id": "NCT90000002", "eligibility_text": "Inclusion Criteria: Female participants, 18 to 75 years. Exclusion Criteria: Pregnancy or breastfeeding.", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "Inclusion Criteria: Female participants, 18 to 75 years"}, {"type": "INCLUSION", "field": "age", "operator": "<=", "value": 75, "unit": "years", "evidence_text": "Inclusion Criteria: Female participants, 18 to 75 years"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "Inclusion Criteria: Female participants, 18 to 75 years"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "pregnancy", "unit": null, "evidence_text": "Exclusion Criteria: Pregnancy or breastfeeding"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "breastfeeding", "unit": null, "evidence_text": "Exclusion Criteria: Pregnancy or breastfeeding"}]}
{"nct_id": "NCT90000003", "eligibility_text": "Inclusion: Adults with heart failure, NYHA II-III. Exclusion: Prior treatment within the last 30 days.", "labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "heart failure, nyha ii-iii", "unit": null, "evidence_text": "Inclusion: Adults with heart failure, NYHA II-III"}, {"type": "EXCLUSION", "field": "medication", "operator": "WITHIN_LAST", "value": 30, "unit": "days", "evidence_text": "Exclusion: Prior treatment within the last 30 days"}]}
{"nct_id": "NCT90000004", "eligibility_text": "Inclusion: Age 6 to 17 years, asthma diagnosis. Exclusion: Active infection.", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 6, "unit": "years", "evidence_text": "Inclusion: Age 6 to 17 years, asthma diagnosis"}, {"type": "INCLUSION", "field": "age", "operator": "<=", "value": 17, "unit": "years", "evidence_text": "Inclusion: Age 6 to 17 years, asthma diagnosis"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "active infection", "unit": null, "evidence_text": "Exclusion: Active infection"}]}
{"nct_id": "NCT90000005", "eligibility_text": "Inclusion Criteria: Participants with rheumatoid arthritis. Exclusion Criteria: major surgery in the last 6 months.", "labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "rheumatoid arthritis", "unit": null, "evidence_text": "Inclusion Criteria: Participants with rheumatoid arthritis"}, {"type": "EXCLUSION", "field": "procedure", "operator": "WITHIN_LAST", "value": 6, "unit": "months", "evidence_text": "Exclusion Criteria: major surgery in the last 6 months"}]}
{"nct_id": "NCT90000006", "eligibility_text": "Inclusion: Male or female participants, age >= 18. Exclusion: previous treatment in the last 4 weeks.", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "Inclusion: Male or female participants, age >= 18"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "Inclusion: Male or female participants, age >= 18"}, {"type": "EXCLUSION", "field": "medication", "operator": "WITHIN_LAST", "value": 4, "unit": "weeks", "evidence_text": "Exclusion: previous treatment in the last 4 weeks"}]}
{"nct_id": "NCT90000007", "eligibility_text": "Inclusion Criteria: long covid symptoms for at least 3 months. Exclusion Criteria: uncontrolled psychiatric disorder.", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 3, "unit": "years", "evidence_text": "Inclusion Criteria: long covid symptoms for at least 3 months"}, {"type": "EXCLUSION", "field": "history", "operator": "EXISTS", "value": "manual review needed", "unit": null, "evidence_text": "Exclusion Criteria: uncontrolled psychiatric disorder"}]}
{"nct_id": "NCT90000008", "eligibility_text": "Inclusion: Adults with migraine. Exclusion: pregnancy, breastfeeding, or active infection.", "labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "active infection", "unit": null, "evidence_text": "Exclusion: pregnancy, breastfeeding, or active infection"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "migraine", "unit": null, "evidence_text": "Inclusion: Adults with migraine"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "pregnancy", "unit": null, "evidence_text": "Exclusion: pregnancy, breastfeeding, or active infection"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "breastfeeding", "unit": null, "evidence_text": "Exclusion: pregnancy, breastfeeding, or active infection"}]}
{"nct_id": "NCT00068003", "eligibility_text": "* ELIGIBILITY CRITERIA FOR PATIENTS WITH A CURRENT DIAGNOSIS OF CANCER:. INCLUSION CRITERIA:. * Patients must have a form of cancer currently being studied in the NCI-SB.. * Patient is able to understand and willing to sign a written informed consent document.. * Age greater than or equal to 18 years.. * Clinical performance status of ECOG 0 or 1.. * Serology. * Seronegative for HIV antibody. (The experimental treatments being evaluated depend upon an intact immune system. Patients who are HIV seropositive can have decreased immune-competence and thus may be less responsive to the experimental treatment and more susceptible to its toxicities).. * Seronegative for hepatitis B surface antigen and seronegative for hepatitis C antibody. If hepatitis C antibody test is positive, then the patient must be tested for the presence of antigen by RT-PCR and be HCV RNA negative.. * Lesions which will be harvested for the generation of TIL should be accessible via standard surgical or radiological techniques and be associated with acceptable morbidity.. EXCLUSION CRITERIA:. * Active systemic infections, coagulation disorders, or other major medical illnesses of the cardiovascular, respiratory, or immune system.. * Patients who cannot give proper informed consent to the experimental therapy due to an active psychiatric disorder or inability to understand the nature of the proposed therapy and attendant risk.. * Women of child-bearing potential who are pregnant because of the potentially dangerous effects of some of the procedures (e.g., tumor biopsy or surgery for tumor resection) on the fetus.. ELIGIBILITY CRITERIA FOR HEALTHY VOLUNTEERS:. INCLUSION CRITERIA for PBMC Donors:. * Age greater than or equal to 18 years.. * Non-reactive for HBsAg, anti-HBc, anti-HCV, anti-HIV-1/2, HBV/HCV/HIV-1 NAT, anti-HTLV-I/II, anti-T. cruzi, West Nile Virus NAT,syphilis, and babesia.. * PBMC donors must meet the strict behavioral and medical history requirements as per applicable NCI-SB Apheresis Donor SOP(s).. INCLUSION CRITERIA FOR WHOLE BLOOD DONORS:. * Age greater than or equal to 18 years.. * Whole blood donors must meet the DTM inclusion criteria for allogeneic whole blood donation.. EXCLUSION CRITERIA for PBMC Donors:. * Has had babesiosis.. * Is at risk or has Creutzfeldt-Jakob Disease.. * Is on steroid therapy or any other medication or has received vaccination that might interfere with cell preparation per Principal Investigator s (PI) discretion.. * Has ongoing illness that would cause harm to the volunteer during the apheresis procedure as determined by the PI.. * Has had yellow jaundice, liver disease, or hepatitis since the age of 11.. * Has uncontrolled diabetes.. * Has a hematologic malignancy or any bleeding abnormalities.. * Has received any type of organ transplant in the past 12 months.. * Has undergone xenotransplantation at any time.. * Has received a dura mater graft.. * If female, is pregnant or has given birth within the last six weeks.. * Has had an ear or body piercing or tattoos within the past 12 months.. * Has had a blood transfusion within the past 12 months.. * Has spent time outside the United States to a restricted country.. * Has participated in any high-risk activities.. EXCLUSION CRITERIA for Whole Blood Donors:. \\- Whole blood donors who do not meet the DTM criteria for allogeneic whole blood donation.", "labeled_rules": [{"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* If female, is pregnant or has given birth within the last six weeks"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Women of child-bearing potential who are pregnant because of the potentially dangerous effects of some of the procedures (e.g., tumor biopsy or surgery for tumor resection) on the fetus"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "eligibility for", "unit": null, "evidence_text": "* ELIGIBILITY CRITERIA FOR PATIENTS WITH A CURRENT DIAGNOSIS OF CANCER:"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "acceptable morbidity", "unit": null, "evidence_text": "* Lesions which will be harvested for the generation of TIL should be accessible via standard surgical or radiological techniques and be associated with acceptable morbidity"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "pregnancy", "unit": null, "evidence_text": "* If female, is pregnant or has given birth within the last six weeks"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "pregnancy", "unit": null, "evidence_text": "* Women of child-bearing potential who are pregnant because of the potentially dangerous effects of some of the procedures (e.g., tumor biopsy or surgery for tumor resection) on the fetus"}]}
{"nct_id": "NCT00552903", "eligibility_text": "Inclusion Criteria:. * Diagnosis of type 2 diabetes (medication and HbA1c\\>7% and no cardiovascular disease), coronary artery disease (history of myocardial infarction or revascularisation) or heart failure (NYHA II-III and admitted in a hospital for the condition within 2 years). * Aged 45 years or older. * Resident in the Päijät-Häme health care district. Exclusion Criteria:. * Classified as ineligible by primary care physician. * Unable to co-operate or participate in health coaching. * Major elective surgery planned within 6 months. * History of major surgery within past 2 years. * Life expectancy \\<1 year. * Pregnancy", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 45, "unit": "years", "evidence_text": "* Aged 45 years or older"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "major surgery within past 2 years", "unit": null, "evidence_text": "* History of major surgery within past 2 years"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "pregnancy", "unit": null, "evidence_text": "* Pregnancy"}]}
{"nct_id": "NCT01316497", "eligibility_text": "Inclusion Criteria:. * Children admitted for surgery for congenital heart disease. Exclusion Criteria:. * heart surgeries of low complexity such as closure of septal defects, aortico-pulmonary windows, establishment of glenn shunts, subaortic membrane resection, redirection of anomalous pulmonary veins, valvotomies, repair of pulmonary artery stenosis and surgeries without the use of extracorporeal circulation", "labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "study-specific condition", "unit": null, "evidence_text": "Inclusion Criteria:"}, {"type": "INCLUSION", "field": "history", "operator": "EXISTS", "value": "manual review needed", "unit": null, "evidence_text": "* Children admitted for surgery for congenital heart disease"}]}
{"nct_id": "NCT00001302", "eligibility_text": "Biopsy proven metastatic cancer, for whom no better therapy exists. All patients are eligible. Enrollment of patients with kidney, breast, ovarian cancers, and lymphomas is encouraged.. A life expectancy of at least 16 weeks, and a performance status (Karnofsky scale) of 70% or greater. Patients without rapidly growing disease.. Any prior therapy except for previous bone marrow transplantation.. WBC greater than 3,000/mm3 and ACG greater than 1,000/mm3; platelets greater than 100,000/mm3.. Creatinine Clearance greater than 50 ml/min; bilirubin less than 1.5 mg/dl; SGOT less than 70u/L; SGPT less than 80u/L.. A signed informed consent and geographic accessibility for the patient to return for follow up and treatment.. No history of brain metastases.. Not currently receiving treatment with the following agents or any other agent known to significantly interact with cyclosporine, and treatment cannot be discontinued, or changed to another therapeutically equivalent allowable drug: acetazolamide, barbiturates, corticosteroids, diltiazem, erythromycin, fluconazole, ketoconazole, nicardipine, phenothiazines, phenytoin, rifampin, sulfonamides, trimethoprim, verapamil, tamoxifen, progesterone, quinine, quinidine, or amiodarone.. No symptomatic peripheral neuropathy (grade 2 or greater arising from prior vinca alkaloid therapy).. No positive serology for HIV.. No ongoing pregnancy or unwillingness to practice adequate contraception.", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 16, "unit": "years", "evidence_text": "A life expectancy of at least 16 weeks, and a performance status (Karnofsky scale) of 70% or greater"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "brain metastases", "unit": null, "evidence_text": "No history of brain metastases"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "kidney, breast, ovarian cancers, and lymphomas", "unit": null, "evidence_text": "Enrollment of patients with kidney, breast, ovarian cancers, and lymphomas is encouraged"}]}
{"nct_id": "NCT00001677", "eligibility_text": "Ability to provide informed consent to all aspects of the study after full information is provided.. Age equal to or older than 18.. A diagnosis of Rheumatoid Arthritis (RA) of more than 6 months as defined by the revised American College of Rheumatology criteria.. Active RA defined as: 6 or more swollen joints;. 6 or more tender joints;. ESR greater than 28 mm/hr (or CRP greater than 0.8) or morning stiffness greater than 45 minutes.. Incomplete response (defined as persistently active disease as described above) to treatment with at least one of the following regimens for over 3 months:. MTX alone (greater than or equal to 17.5 mg/week);. MTX (greater than or equal to 17.5 mg/week) plus HCQ (greater than or equal to 200 mg/day);. MTX (greater than or equal to 17.5 mg/week) plus SSZ (greater than or equal to 1 gm/d);. MTX (greater than or equal to 17.5 mg/week) plus CsA (1-3 mg/kg/day);. MTX (greater than or equal to 17.5 mg/week) plus SSZ (greater than 1 gm/day) plus HCQ (greater than or equal to 200 mg/day);. No requirement of corticosteroids in doses equivalent to over 10 mg/d prednisone nor other immunosuppressive agents required for the control of extraarticular manifestations at the time of study entry.. No active acute or chronic infections requiring antibiotic therapy, serious viral infections (such as hepatitis, herpes zoster, or HIV), or serious fungal infections. Patients with a positive PPD who have not received INH or other antituberculous therapy will be excluded.. No pregnant women, nursing mothers, or patients of childbearing age not practicing birth control.. No preexisting malignancy other than basal cell carcinoma.. No history of stroke, seizure disorder, or chronic neurologic disease.. No unstable coronary artery disease, cardiomyopathy, conduction heart block greater than first degree, or a dysrhythmia requiring therapy.. No confounding medical illness that in the judgment of the investigators would pose added risk for study participants (e.g., chronic hepatic, renal, or pulmonary disease or bone marrow hypoplasia).. No presence of seronegative spondyloarthropathy, systemic lupus erythematosus, systemic sclerosis, inflammatory myopathy, systemic vasculitis, psoriasis, or inflammatory bowel disease.. No serum creatinine greater than 2.0 mg/dL on at least 2 different occasions which is sustained for at least 1 month.. No hematocrit less than 28% (or hemoglobin less than 9.0 mg/dL), or platelet count less than 100,000, or white blood count less than 3,500/dL.. No patients with active lung disease, patients with a chronic and progressive lung disease, or patients with a chronic but stable lung disease with pulmonary function tests of less than 70% of predicted (DLCO less than 60%).. No patients with hypogammaglobulinemia (IgG count less than 300).. No patients treated with alkylating agents for over 1 year at any time or treated with a purine nucleoside analog at any time.", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "Age equal to or older than 18"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 2, "unit": "years", "evidence_text": "No serum creatinine greater than 2.0 mg/dL on at least 2 different occasions which is sustained for at least 1 month"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 1, "unit": "years", "evidence_text": "No patients treated with alkylating agents for over 1 year at any time or treated with a purine nucleoside analog at any time"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 3, "unit": "years", "evidence_text": "Incomplete response (defined as persistently active disease as described above) to treatment with at least one of the following regimens for over 3 months:"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 10, "unit": "years", "evidence_text": "No requirement of corticosteroids in doses equivalent to over 10 mg/d prednisone nor other immunosuppressive agents required for the control of extraarticular manifestations at the time of study entry"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "No pregnant women, nursing mothers, or patients of childbearing age not practicing birth control"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "stroke, seizure disorder, or chronic neurologic", "unit": null, "evidence_text": "No history of stroke, seizure disorder, or chronic neurologic disease"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "no pregnant women, nursing mothers, or", "unit": null, "evidence_text": "No pregnant women, nursing mothers, or patients of childbearing age not practicing birth control"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "a purine nucleoside analog at any", "unit": null, "evidence_text": "No patients treated with alkylating agents for over 1 year at any time or treated with a purine nucleoside analog at any time"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "no with active lung disease", "unit": null, "evidence_text": "No patients with active lung disease, patients with a chronic and progressive lung disease, or patients with a chronic but stable lung disease with pulmonary function tests of less than 70% of predicted (DLCO less than 60%)"}]}
{"nct_id": "NCT00001885", "eligibility_text": "* INCLUSION CRITERIA:. Individuals 21 years of age or older with any of the following:. RA (based on 1987 American College of Rheumatology Revised Criteria for the Classification of RA) with PF (biopsy-proven), or. RA-only, or. Biopsy-proven idiopathic PF-only, or. Healthy research volunteers.. EXCLUSION CRITERIA:. Individuals with any of the following:. Inhalational exposure to fibrogenic fibers or dusts (e.g., asbestos, silica, coal, beryllium).. Chronic pulmonary disorders other than pulmonary fibrosis.. Other collagen vascular disorders (e.g., systemic lupus erythematosus, scleroderma, polymyositis, mixed connective tissue disease).. Non-rheumatoid arthritis.. Viral infections associated with PF (e.g., hepatitis B, hepatitis C, human immunodeficiency virus).. Pregnancy.", "labeled_rules": [{"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "pregnancy", "unit": null, "evidence_text": "Pregnancy"}, {"type": "INCLUSION", "field": "history", "operator": "EXISTS", "value": "manual review needed", "unit": null, "evidence_text": "Individuals 21 years of age or older with any of the following:"}]}
{"nct_id": "NCT00002781", "eligibility_text": "DISEASE CHARACTERISTICS: Biopsy-proven melanoma that is clinical stage III Estimated clinical tumor depth 1.0-6.0 cm from the epidermis Tumor surface diameter no greater than 10 cm Grossly evident cutaneous or subcutaneous tumor nodules are eligible for irradiation. PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 70%-100% Life expectancy: More than 3 months Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: No history of phenylketonuria Negative serum pregnancy test required of fertile women Adequate contraception required of fertile women during and for 6 months after the study. PRIOR CONCURRENT THERAPY: No prior radiotherapy to the target area", "labeled_rules": [{"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 70%-100% Life expectancy: More than 3 months Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: No history of phenylketonuria Negative serum pregnancy test required of fertile women Adequate contraception required of fertile women during and for 6 months after the study"}, {"type": "INCLUSION", "field": "history", "operator": "EXISTS", "value": "manual review needed", "unit": null, "evidence_text": "PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 70%-100% Life expectancy: More than 3 months Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: No history of phenylketonuria Negative serum pregnancy test required of fertile women Adequate contraception required of fertile women during and for 6 months after the study"}]}
{"nct_id": "NCT00003750", "eligibility_text": "DISEASE CHARACTERISTICS:. * Histologically confirmed neuroblastoma or melanoma at original diagnosis. * Refractory to chemotherapy or recurrence after prior multiagent chemotherapy. * Measurable or evaluable (detectable by bone scan) metastatic disease OR. * No evidence of disease if complete response to prior surgical resection, radiotherapy, and/or chemotherapy OR. * Histologically confirmed tumor expressing GD2 antigen at original diagnosis or relapse. * Refractory to standard treatment. * Measurable or evaluable disease by clinical assessments or laboratory markers OR. * No evidence of disease after prior surgical resection of metastatic, recurrent disease. * Histologically confirmed recurrent osteogenic sarcoma after prior chemotherapy allowed. * Soft tissue sarcoma allowed. * No primary CNS tumors. * Prior CNS metastases allowed, provided:. * Disease previously treated. * Disease clinically stable for 4 weeks before study. * At least 4 weeks since prior steroids for CNS metastases. * No clinically detectable pleural effusions or ascites. PATIENT CHARACTERISTICS:. Age:. * 21 and under. Performance status:. * Karnofsky 60-100% for children over age 10. * Lansky 60-100% for children age 10 and under. Life expectancy:. * At least 12 weeks. Hematopoietic:. * Absolute neutrophil count greater than 1,000/mm\\^3. * Platelet count at least 75,000/mm\\^3 (transfusion allowed). * Hemoglobin at least 9.0 g/dL (transfusion allowed). Hepatic:. * Bilirubin less than 1.5 mg/dL. * ALT or AST no greater than 2.5 times normal. * Hepatitis B surface antigen negative. Renal:. * Creatinine no greater than 1.5 mg/dL OR. * Creatinine clearance or radioisotope glomerular filtration rate at least 60 mL/min. Cardiovascular:. * Shortening fraction at least 27% by echocardiogram OR. * Ejection fraction more than 50% by MUGA scan. * No congestive heart failure. * No uncontrolled cardiac rhythm disturbance. Pulmonary:. * FEV\\_1 and FVC more than 60% of predicted OR. * No dyspnea at rest. * No exercise intolerance. * Oxygen saturation more than 94% by pulse oximetry on room air. Neurologic:. * No seizure disorders requiring antiseizure medications. * No significant neurologic deficit or grade 2 or greater objective peripheral neuropathy. Other:. * Not pregnant or nursing. * Negative pregnancy test. * Fertile patients must use effective contraception. * HIV negative. * No significant concurrent illnesses unrelated to cancer or its treatment. * No significant psychiatric disabilities. * No uncontrolled active infections. * No uncontrolled active peptic ulcer. PRIOR CONCURRENT THERAPY:. Biologic therapy:. * At least 1 week since prior growth factors. * At least 1 week since prior immunomodulatory therapy. * Prior monoclonal antibodies allowed if no detectable antibody to hu14.18. * Prior autologous bone marrow transplantation (BMT) or stem cell transplantation (SCT) allowed. * Prior autologous BMT or SCT with monoclonal antibody-purged specimens allowed. * No concurrent growth factors. * No concurrent interferon. Chemotherapy:. * See Disease Characteristics. * At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas, mitomycin, or melphalan). * No concurrent palliative chemotherapy. Endocrine therapy:. * See Disease Characteristics. * At least 2 weeks since prior glucocorticoids, except for life-threatening symptoms. * No concurrent corticosteroids. * No concurrent glucocorticoids, except for life-threatening symptoms. Radiotherapy:. * See Disease Characteristics. * At least 3 weeks since prior radiotherapy. * No concurrent palliative radiotherapy. Surgery:. * See Disease Characteristics. * At least 2 weeks since prior major surgery (e.g., laparotomy or thoracotomy). * No prior organ allografts. * No concurrent palliative surgery. Other:. * Recovered from prior therapy. * At least 1 week since prior tretinoin. * At least 3 weeks since prior immunosuppressive therapy. * No other concurrent immunosuppressive drugs", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 12, "unit": "years", "evidence_text": "* At least 12 weeks"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 1, "unit": "years", "evidence_text": "* At least 1 week since prior tretinoin"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 3, "unit": "years", "evidence_text": "* At least 3 weeks since prior radiotherapy"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 1, "unit": "years", "evidence_text": "* At least 1 week since prior growth factors"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 9, "unit": "years", "evidence_text": "* Hemoglobin at least 9.0 g/dL (transfusion allowed)"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 1, "unit": "years", "evidence_text": "* At least 1 week since prior immunomodulatory therapy"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 27, "unit": "years", "evidence_text": "* Shortening fraction at least 27% by echocardiogram OR"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 3, "unit": "years", "evidence_text": "* At least 3 weeks since prior immunosuppressive therapy"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 4, "unit": "years", "evidence_text": "* At least 4 weeks since prior steroids for CNS metastases"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 75, "unit": "years", "evidence_text": "* Platelet count at least 75,000/mm\\^3 (transfusion allowed)"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 2, "unit": "years", "evidence_text": "* At least 2 weeks since prior major surgery (e.g., laparotomy or thoracotomy)"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 60, "unit": "years", "evidence_text": "* Creatinine clearance or radioisotope glomerular filtration rate at least 60 mL/min"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 2, "unit": "years", "evidence_text": "* At least 2 weeks since prior glucocorticoids, except for life-threatening symptoms"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 3, "unit": "years", "evidence_text": "* At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas, mitomycin, or melphalan)"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "fertile", "unit": null, "evidence_text": "* Fertile patients must use effective contraception"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "monoclonal antibody-purged specimens allowed", "unit": null, "evidence_text": "* Prior autologous BMT or SCT with monoclonal antibody-purged specimens allowed"}]}
{"nct_id": "NCT00004810", "eligibility_text": "PROTOCOL ENTRY CRITERIA:. * Mildly to moderately severe ulcerative colitis. * Patient age: 18 to 80", "labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "study-specific condition", "unit": null, "evidence_text": "PROTOCOL ENTRY CRITERIA:"}, {"type": "INCLUSION", "field": "history", "operator": "EXISTS", "value": "manual review needed", "unit": null, "evidence_text": "* Mildly to moderately severe ulcerative colitis"}]}
{"nct_id": "NCT00004925", "eligibility_text": "DISEASE CHARACTERISTICS:. * Histologically or cytologically confirmed locally advanced, inflammatory, or metastatic adenocarcinoma of the breast that has been treated with no more than 1 prior systemic cytotoxic regimen. * Overexpression of HER2 protein (2+ or 3+). * Evaluable disease. * History of brain metastases allowed if off steroids and asymptomatic, with a 3 month or greater interval since last dose of brain irradiation, and no evidence of progression. * Hormone receptor status:. * Not specified. PATIENT CHARACTERISTICS:. Age:. * 18 and over. Sex:. * Female. Menopausal status:. * Not specified. Performance status:. * ECOG 0-1. Life expectancy:. * Not specified. Hematopoietic:. * Absolute neutrophil count at least 1,500/mm\\^3. * Platelet count at least 100,000/mm\\^3. * Hemoglobin at least 10 g/dL. Hepatic:. * Bilirubin no greater than 1.5 times upper limit of normal (ULN). Renal:. * AST or ALT no greater than 4 times ULN. Cardiovascular:. * Adequate cardiac function. * LVEF at least 50% predicted or lower limit of normal. Other:. * Not pregnant or nursing. * Negative pregnancy test. * Fertile patients must use effective contraception. * No other concurrent medical or psychological condition that would preclude study compliance. * No history of hypersensitivity to anthracyclines, eggs, or egg products. PRIOR CONCURRENT THERAPY:. Biologic therapy:. * Prior trastuzumab (Herceptin) allowed. Chemotherapy:. * See Disease Characteristics. * At least 3 weeks since prior antineoplastic therapy. * No more than 1 prior systemic cytotoxic regimen for locally advanced, metastatic, or inflammatory breast cancer. * No prior anthracyclines greater than 240 mg/m2. * No other concurrent antineoplastic agents. * No concurrent treatment with other liposomal products other than doxorubicin HCl liposome. Endocrine therapy:. * See Disease Characteristics. * At least 3 weeks since prior hormonal agents. * No concurrent hormonal therapy. Radiotherapy:. * See Disease Characteristics. Surgery:. * Not specified. Other:. * At least 3 weeks since other prior investigational drugs", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 10, "unit": "years", "evidence_text": "* Hemoglobin at least 10 g/dL"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 100, "unit": "years", "evidence_text": "* Platelet count at least 100,000/mm\\^3"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 3, "unit": "years", "evidence_text": "* At least 3 weeks since prior hormonal agents"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 1, "unit": "years", "evidence_text": "* Absolute neutrophil count at least 1,500/mm\\^3"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 3, "unit": "years", "evidence_text": "* At least 3 weeks since prior antineoplastic therapy"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 50, "unit": "years", "evidence_text": "* LVEF at least 50% predicted or lower limit of normal"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 3, "unit": "years", "evidence_text": "* At least 3 weeks since other prior investigational drugs"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Female"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "fertile", "unit": null, "evidence_text": "* Fertile patients must use effective contraception"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "hypersensitivity to anthracyclines, eggs, or egg", "unit": null, "evidence_text": "* No history of hypersensitivity to anthracyclines, eggs, or egg products"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "other liposomal products other than doxorubicin", "unit": null, "evidence_text": "* No concurrent treatment with other liposomal products other than doxorubicin HCl liposome"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "no more than 1 prior systemic", "unit": null, "evidence_text": "* Histologically or cytologically confirmed locally advanced, inflammatory, or metastatic adenocarcinoma of the breast that has been treated with no more than 1 prior systemic cytotoxic regimen"}]}
{"nct_id": "NCT00018122", "eligibility_text": "Type 1 diabetics that have received a kidney transplant as well as (under Project 1) Islet Cell Transplant. A control group of 8 kidney transplant recipients who do not have diabetes will also be sought. Age range for both groups is expected to fall in the 25-50 year/old range based upon statistical data, although those between the ages of 18 and 65 may also qualify.", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 25, "unit": "years", "evidence_text": "Age range for both groups is expected to fall in the 25-50 year/old range based upon statistical data, although those between the ages of 18 and 65 may also qualify"}, {"type": "INCLUSION", "field": "age", "operator": "<=", "value": 50, "unit": "years", "evidence_text": "Age range for both groups is expected to fall in the 25-50 year/old range based upon statistical data, although those between the ages of 18 and 65 may also qualify"}]}
{"nct_id": "NCT00048542", "eligibility_text": "Inclusion Criteria:. * Subjects must have a diagnosis of polyarticular juvenile idiopathic arthritis (JIA) age 4 to 17 by the American College of Rheumatology (ACR) criteria. Disease onset may have been systemic, polyarticular, or pauciarticular. If the disease was systemic onset, then the subjects must be free of any systemic JIA manifestations for at least 3 months before the time of qualification.. * At the time of study screening, the subject must have continuing active disease defined as \\>= 5 swollen joints and \\>= 3 joints with limitation of motion (LOM). These joints are not mutually exclusive.. * Subjects may be either naïve to MTX, inadequate responders to MTX, or intolerant to MTX. Intolerance to MTX will be defined by the subject's physician. The MTX must be maintained at a dose of at least 10 mg/m2 body surface area/week for a minimum of 3 months, prior to screening.. * Duration of disease is not limited, but must have been long enough for a subject to have been given an adequate trial of nonsteroidal anti-inflammatory drugs (NSAIDs).. * Have not received other disease-modifying anti-rheumatic drugs (DMARDs) including penicillamine, hydroxychloroquine, sulfasalazine, oral or injectable gold, cyclosporin; or intravenous immunoglobulin (IV Ig); or cytotoxic agents, for at least 4 weeks prior to receiving 1st dose of study drug. Subjects currently on one or more of these DMARDs must demonstrate active disease (defined above) prior to a minimum 4 weeks (28 days) washout of all DMARDs.. * Subjects who are refractory to MTX after 3 months of treatment must demonstrate active disease (defined above) prior to enrollment in the open-label part of the trial.. * Have not received an intra-articular glucocorticoid injection within 4 weeks (28 days) prior to enrollment into the study.. * Have good venous access and stable hematocrit \\>= 24%.. * All sexually active male and female study participants must be practicing adequate contraception. Post-pubertal females must have a negative serum pregnancy test no greater than 10 days prior to the first dose of study drug.. * Parent or guardian has voluntarily signed and dated an informed consent form, approved by an Institutional Review Board (IRB)/Independent Ethics Committee (IEC), after the nature of the study has been explained and the subject's parent or legal guardian has had the opportunity to ask questions.. Exclusion Criteria:. * Pregnant or nursing female.. * Functional class IV by ACR criteria.. * Laboratory parameters outside limits established in the protocol.. * Medical history, medical condition, or previous treatment not allowed by the protocol.", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 4, "unit": "years", "evidence_text": "or cytotoxic agents, for at least 4 weeks prior to receiving 1st dose of study drug"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 10, "unit": "years", "evidence_text": "The MTX must be maintained at a dose of at least 10 mg/m2 body surface area/week for a minimum of 3 months, prior to screening"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 3, "unit": "years", "evidence_text": "If the disease was systemic onset, then the subjects must be free of any systemic JIA manifestations for at least 3 months before the time of qualification"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Pregnant or nursing female"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* All sexually active male and female study participants must be practicing adequate contraception"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "pregnancy", "unit": null, "evidence_text": "* Pregnant or nursing female"}]}
{"nct_id": "NCT00054145", "eligibility_text": "DISEASE CHARACTERISTICS:. * Histologically or cytologically confirmed breast cancer. * Recurrent or refractory, locally advanced or metastatic disease. * At least 1 unidimensionally measurable lesion. * At least 20 mm by conventional techniques OR 10 mm by spiral CT scan. * Previously irradiated lesions are not considered measurable unless they have demonstrated progression before study entry. * No measurable disease limited to bone lesions. * No known brain metastases. * Hormone receptor status:. * Not specified. PATIENT CHARACTERISTICS:. Age. * 18 and over. Sex. * Male or female. Menopausal status. * Not specified. Performance status. * ECOG 0-2 OR. * Karnofsky 60-100%. Life expectancy. * More than 3 months. Hematopoietic. * WBC at least 3,000/mm\\^3. * Absolute neutrophil count at least 1,500/mm\\^3. * Platelet count at least 100,000/mm\\^3. * No history of hemolytic disorder. Hepatic. * Bilirubin no greater than 1.25 times upper limit of normal (ULN). * AST/ALT no greater than 2.5 times ULN (5 times ULN if liver metastases present). Renal. * Creatinine normal OR. * Creatinine clearance at least 60 mL/min. Cardiovascular. * No symptomatic congestive heart failure. * No unstable angina pectoris. * No cardiac arrhythmia. * No evidence of cardiac dysfunction. Gastrointestinal. * No history of biliary flow obstruction. * No abnormalities of the gastrointestinal tract that would preclude study drug absorption. * No active peptic ulcer disease. Other. * Not pregnant or nursing. * Negative pregnancy test. * Fertile patients must use effective contraception. * No ongoing or active infection. * No poorly controlled diabetes mellitus. * No other uncontrolled illness. * No prior allergic reactions to compounds of similar chemical or biological composition to perifosine. * No psychiatric illness or social situation that would preclude study compliance. PRIOR CONCURRENT THERAPY:. Biologic therapy. * Not specified. Chemotherapy. * No more than 2 prior lines of chemotherapy for advanced disease, excluding adjuvant chemotherapy. * Prior adjuvant chemotherapy allowed. * At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered. Endocrine therapy. * At least 4 weeks since prior endocrine therapy. * Multiple lines of endocrine therapy for advanced disease allowed. Radiotherapy. * At least 4 weeks since prior radiotherapy and recovered. * Prior radiotherapy for metastatic disease allowed. Surgery. * No prior major gastric surgery. * Prior surgery, including for metastatic disease, allowed. Other. * No other concurrent anticancer or investigational agents. * No concurrent antiretroviral therapy in HIV-positive patients. * Concurrent bisphosphonates allowed", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 3, "unit": "years", "evidence_text": "* WBC at least 3,000/mm\\^3"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 100, "unit": "years", "evidence_text": "* Platelet count at least 100,000/mm\\^3"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 60, "unit": "years", "evidence_text": "* Creatinine clearance at least 60 mL/min"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 1, "unit": "years", "evidence_text": "* At least 1 unidimensionally measurable lesion"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 1, "unit": "years", "evidence_text": "* Absolute neutrophil count at least 1,500/mm\\^3"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 4, "unit": "years", "evidence_text": "* At least 4 weeks since prior endocrine therapy"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 4, "unit": "years", "evidence_text": "* At least 4 weeks since prior radiotherapy and recovered"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 20, "unit": "years", "evidence_text": "* At least 20 mm by conventional techniques OR 10 mm by spiral CT scan"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 4, "unit": "years", "evidence_text": "* At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Male or female"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "hemolytic disorder", "unit": null, "evidence_text": "* No history of hemolytic disorder"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "biliary flow obstruction", "unit": null, "evidence_text": "* No history of biliary flow obstruction"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "fertile", "unit": null, "evidence_text": "* Fertile patients must use effective contraception"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "no concurrent antiretroviral therapy in hiv-positive", "unit": null, "evidence_text": "* No concurrent antiretroviral therapy in HIV-positive patients"}]}
{"nct_id": "NCT00055926", "eligibility_text": "Inclusion Criteria:. * Histologically or cytologically confirmed HER2-overexpressing breast cancer. * Prior or newly documented HER2 amplification by fluorescence in situ hybridization (FISH). * Progressive metastatic disease. * Must have received at least one prior chemotherapy regimen for metastatic breast cancer. * At least 1 measurable or evaluable lesion. * At least 1 lesion accessible for 2 separate core biopsies for pharmacodynamic evaluation. * 18 and over. * Male or female. * ECOG 0-1. * Life expectancy, More than 3 months. * Hematopoietic. * Absolute neutrophil count at least 1,500/mm\\^3\\*. * Platelet count at least 100,000/mm\\^3\\* NOTE: \\*Without hematopoietic growth factors or transfusions. * Hepatic. * Bilirubin no greater than 1.5 mg/dL. * AST/ALT no greater than 2.5 times upper limit of normal (ULN) (5 times ULN if liver metastases are present). * Renal. * Creatinine no greater than 1.5 times ULN OR. * Creatinine clearance at least 60 mL/min. * Cardiovascular. * 12-lead ECG with normal tracing. * history of cardiovascular disease (i.e., ischemic heart disease, arrhythmia, or congestive heart failure) unless asymptomatic for the past year with no requirement for antiarrhythmics or a clinically significant medical management change. * Gastrointestinal. * Able to take oral medication\\* Negative pregnancy test. * Fertile patients must use effective contraception. * At least 4 weeks since prior trastuzumab (Herceptin). * At least 4 weeks since other prior biologic therapy or immunotherapy. * At least 4 weeks since prior chemotherapy (6 weeks for mitomycin or nitrosoureas). * At least 6 months since prior doxorubicin or doxorubicin equivalents without any prior or developing signs or symptoms of cardiomyopathy. * No cumulative doses of more than 300 mg/m\\^2. * At least 2 weeks since prior hormonal therapy for the primary disease. * Concurrent hormone replacement therapy or luteinizing hormone-releasing hormone agonists allowed. * At least 4 weeks since prior radiotherapy. * At least 3 weeks since prior major surgery (2 weeks for minor surgery). * Recovered from prior therapy. * At least 4 weeks since prior investigational treatment. * Coumarin or heparin derivatives allowed for the prevention of deep vein thrombosis or port patency. Exclusion Criteria:. * known or clinically suspected brain metastases or leptomeningeal disease. * symptomatic edema or third-space fluid (e.g., ascites or pleural effusions). * known hepatitis B or C infection. * significant ECG changes that require medical intervention. * QTc interval less than 460 msec. * No history of torsade or other symptomatic QTc abnormality. * LVEF greater than 50% by MUGA. * gastrointestinal abnormality that would require medications (including all antacids). * persistent symptoms of an esophageal or digestive disorder. * pregnant or nursing. * known HIV infection. * active infection. * concurrent uncontrolled systemic disorders or laboratory abnormalities that would preclude study drug safety evaluation. * mental disorder that would preclude study compliance or ability to give informed consent. * No more than 2 prior trastuzumab-based regimens for advanced disease. * concurrent immunotherapy. * more than 1 prior anthracycline- or anthracenedione-containing regimen (except with approval of the sponsor). * prior high-dose chemotherapy with hematopoietic stem cell transplantation. * concurrent anticancer chemotherapy. * No concurrent anticancer hormonal therapy, including tamoxifen. * prior radiotherapy to the only disease site that would be assessed for response. * concurrent radiotherapy. * prior partial or complete gastrectomy. * concurrent antiarrhythmics. * concurrent antacids. * concurrent anticoagulant at therapeutic doses. * other concurrent experimental anticancer medications for breast cancer", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 60, "unit": "years", "evidence_text": "* Creatinine clearance at least 60 mL/min"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 1, "unit": "years", "evidence_text": "* At least 1 measurable or evaluable lesion"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 4, "unit": "years", "evidence_text": "* At least 4 weeks since prior radiotherapy"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 1, "unit": "years", "evidence_text": "* Absolute neutrophil count at least 1,500/mm\\^3\\*"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 4, "unit": "years", "evidence_text": "* At least 4 weeks since prior trastuzumab (Herceptin)"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 4, "unit": "years", "evidence_text": "* At least 4 weeks since prior investigational treatment"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 4, "unit": "years", "evidence_text": "* At least 4 weeks since other prior biologic therapy or immunotherapy"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 2, "unit": "years", "evidence_text": "* At least 2 weeks since prior hormonal therapy for the primary disease"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 3, "unit": "years", "evidence_text": "* At least 3 weeks since prior major surgery (2 weeks for minor surgery)"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 4, "unit": "years", "evidence_text": "* At least 4 weeks since prior chemotherapy (6 weeks for mitomycin or nitrosoureas)"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 1, "unit": "years", "evidence_text": "* At least 1 lesion accessible for 2 separate core biopsies for pharmacodynamic evaluation"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 100, "unit": "years", "evidence_text": "* Platelet count at least 100,000/mm\\^3\\* NOTE: \\*Without hematopoietic growth factors or transfusions"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 6, "unit": "years", "evidence_text": "* At least 6 months since prior doxorubicin or doxorubicin equivalents without any prior or developing signs or symptoms of cardiomyopathy"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Male or female"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "active infection", "unit": null, "evidence_text": "* active infection"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hiv positive", "unit": null, "evidence_text": "* known HIV infection"}]}
{"nct_id": "NCT00060125", "eligibility_text": "Inclusion Criteria:. * Histological or cytological diagnosis of cutaneous melanoma and clinical evidence of distant metastatic, non-resectable regional lymphatic, or extensive in transit recurrent disease. * Patients must have at least 2 cutaneous lesions amenable to excisional biopsy for correlative studies; in addition, patients must have measurable disease; the disease remaining after the first excisional biopsy must be measurable; lesions that are considered intrinsically non-measurable include the following:. * Bone lesions. * Leptomeningeal disease. * Ascites. * Pleural/pericardial effusion. * Lymphangitis cutis/pulmonis. * Abdominal masses that are not confirmed and followed by imaging techniques. * Cystic lesions. * Lesions that are situated in a previously irradiated area. * No history of brain metastases. * No allergies to azoles (e.g. ketoconazole) or allergies to compounds structurally similar to R115777. * No more than 1 prior immunotherapy regimen for treatment of advanced melanoma; an additional immunologic therapy in the adjuvant setting (e.g. IFN-a) is acceptable; prior chemotherapy for any stage of melanoma is not allowed. * No radiotherapy or immunotherapy within four weeks prior to the initiation of therapy on this study. * CTC (ECOG) performance status 0-1. * Non-pregnant, non-nursing; treatment under this protocol would expose an unborn child to significant risks; women and men of reproductive potential should agree to use an effective means of birth control; women of child-bearing age will undergo pregnancy testing. * ANC \\>= 1500/uL. * Platelets \\>= 100,000/uL. * Bilirubin =\\< 1.5 mg/dL. * Creatinine =\\< 2.0 mg/dL", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 2, "unit": "years", "evidence_text": "* Patients must have at least 2 cutaneous lesions amenable to excisional biopsy for correlative studies"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "women of child-bearing age will undergo pregnancy testing"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "women and men of reproductive potential should agree to use an effective means of birth control"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "women and men of reproductive potential should agree to use an effective means of birth control"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "brain metastases", "unit": null, "evidence_text": "* No history of brain metastases"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "in addition", "unit": null, "evidence_text": "in addition, patients must have measurable disease"}]}
{"nct_id": "NCT00062491", "eligibility_text": "* Confirmed diagnosis of malignant melanoma. * Measurable disease. * Granulocytes ≥1,500/µl, Platelets ≥100,000/µl, Creatinine ≤ULN, Bilirubin ≤1.5 mg/dl, AST ≤2.5 x ULN. * No prior treatment with other camptothecin drug.. * ≥ 21 days since completion of prior chemotherapy, ≥6 weeks since prior Mitomycin-C. * ECOG Performance Status 0-1. * Negative pregnancy test for female patients", "labeled_rules": [{"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Negative pregnancy test for female patients"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "malignant melanoma", "unit": null, "evidence_text": "* Confirmed diagnosis of malignant melanoma"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "negative pregnancy test for female", "unit": null, "evidence_text": "* Negative pregnancy test for female patients"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "other camptothecin drug", "unit": null, "evidence_text": "* No prior treatment with other camptothecin drug"}]}
{"nct_id": "NCT00072085", "eligibility_text": "DISEASE CHARACTERISTICS:. * Diagnosis of metastatic melanoma. * Measurable disease. * Progressive disease during or after prior standard treatment with or without interleukin-2. PATIENT CHARACTERISTICS:. Age. * 16 and over. Performance status. * ECOG 0-2. Life expectancy. * More than 6 months. Hematopoietic. * WBC at least 3,000/mm\\^3. * Platelet count at least 90,000/mm\\^3. * Lymphocyte count greater than 500/mm\\^3. Hepatic. * Bilirubin no greater than 2.0 mg/dL (less than 3.0 mg/dL for patients with Gilbert's syndrome). * ALT and AST less than 3 times normal. * Hepatitis B surface antigen negative. Renal. * Creatinine no greater than 2.0 mg/dL. Cardiovascular. * No symptomatic cardiac disease. Immunologic. * No active systemic infection. * No autoimmune disease. * No known immunodeficiency disease. * No known hypersensitivity to study agents. * No form of primary or secondary immunodeficiency. * No opportunistic infection. * HIV negative. Other. * Not pregnant or nursing. * Negative pregnancy test. * Fertile patients must use effective contraception. PRIOR CONCURRENT THERAPY:. Biologic therapy. * See Disease Characteristics. * No prior gp100 peptide vaccine. Chemotherapy. * More than 6 weeks since prior nitrosoureas. Endocrine therapy. * No concurrent systemic steroid therapy. Radiotherapy. * Not specified. Surgery. * Prior recent (within the past 3 weeks) minor surgical procedures allowed. Other. * Recovered from prior therapy (toxicity no greater than grade 1). * More than 3 weeks since prior systemic anticancer therapy. * No other concurrent systemic anticancer therapy", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 3, "unit": "years", "evidence_text": "* WBC at least 3,000/mm\\^3"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 90, "unit": "years", "evidence_text": "* Platelet count at least 90,000/mm\\^3"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "metastatic melanoma", "unit": null, "evidence_text": "* Diagnosis of metastatic melanoma"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "fertile", "unit": null, "evidence_text": "* Fertile patients must use effective contraception"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "or without interleukin-2", "unit": null, "evidence_text": "* Progressive disease during or after prior standard treatment with or without interleukin-2"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "dl for", "unit": null, "evidence_text": "* Bilirubin no greater than 2.0 mg/dL (less than 3.0 mg/dL for patients with Gilbert's syndrome)"}]}
{"nct_id": "NCT00106535", "eligibility_text": "Inclusion Criteria:. * adult patients at least 18 years of age with moderate to severe active RA for at least 6 months;. * inadequate response to a stable dose of MTX;. * patients of reproductive potential must be using reliable methods of contraception.. Exclusion Criteria:. * major surgery (including joint surgery) within 8 weeks before entering study, or planned surgery within 6 months after entering study;. * prior treatment failure with an anti-tumor necrosis factor agent;. * women who are pregnant or breast-feeding.", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "* adult patients at least 18 years of age with moderate to severe active RA for at least 6 months"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* women who are pregnant or breast-feeding"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "an anti-tumor necrosis factor agent", "unit": null, "evidence_text": "* prior treatment failure with an anti-tumor necrosis factor agent"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "moderate to severe active ra for", "unit": null, "evidence_text": "* adult patients at least 18 years of age with moderate to severe active RA for at least 6 months"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "pregnancy", "unit": null, "evidence_text": "* women who are pregnant or breast-feeding"}]}
{"nct_id": "NCT00111722", "eligibility_text": "Inclusion Criteria:. * Female patient at least 18 years old. * Patient has menses approximately monthly. * Patient has at least a 6 month history of migraine and at least a 6 month history of menstrual migraine. Exclusion Criteria:. * Pregnant and/or nursing mother. * Cardiovascular disease. * Uncontrolled hypertension", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "* Female patient at least 18 years old"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Female patient at least 18 years old"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "migraine and at least a 6", "unit": null, "evidence_text": "* Patient has at least a 6 month history of migraine and at least a 6 month history of menstrual migraine"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "pregnancy", "unit": null, "evidence_text": "* Pregnant and/or nursing mother"}]}
{"nct_id": "NCT00112229", "eligibility_text": "Inclusion Criteria:. * Histologically confirmed stage III or stage IV melanoma. * Tumor expression of Melan-A +/- Tyrosinase. * Human leukocyte antigen-A2 (HLA-A2) positive. Exclusion Criteria:. * Clinically significant heart disease. * Serious illnesses, eg, serious infections requiring antibiotics, bleeding disorders or uncontrolled peptic ulcer, or seizure or central nervous system disorders. * History of immunodeficiency disease or autoimmune disease. * Coagulation or bleeding disorders", "labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "immunodeficiency disease or autoimmune disease", "unit": null, "evidence_text": "* History of immunodeficiency disease or autoimmune disease"}, {"type": "INCLUSION", "field": "history", "operator": "EXISTS", "value": "manual review needed", "unit": null, "evidence_text": "* Histologically confirmed stage III or stage IV melanoma"}]}
{"nct_id": "NCT00116701", "eligibility_text": "Inclusion Criteria: -at least 18 years old - Diagnosis of chronic kidney disease (CKD) and receiving dialysis for at least 3 months prior to screening - Baseline Hb level greater than or equal to 10.0 g/dL and less than or equal to 13.0 g/dL - Adequate iron stores (defined as serum ferritin greater than or equal to 100 µg/L or transferrin saturation \\[TSAT\\] greater than or equal to 20%) - Stable IV (epoetin alfa or beta) or SC rHuEPO (epoetin beta) therapy 2 or 3 times per week for at least 8 weeks before screening (stable is defined as less than 25% change in weekly dose and no change in frequency or route) - All subjects must practice adequate contraception (in the judgment of the investigator) throughout this trial. Exclusion Criteria: - Received SC epoetin alfa in the 12 months before screening - Uncontrolled hypertension (diastolic blood pressure greater than 100 mmHg or systolic blood pressure greater than 180 mmHg on 2 separate occasions during screening) - Prior history (within 12 weeks before enrolment) of cardiovascular events including:. * acute myocardial ischemia;. * hospitalization for congestive heart failure;. * myocardial infarction. - Pregnant or breast-feeding women - Treatment with an investigational agent or device within 30 days before screening or scheduled to receive an investigational agent other than those specified by this protocol during the course of this study - Known sensitivity to any of the products to be administered during dosing - Disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "Inclusion Criteria: -at least 18 years old - Diagnosis of chronic kidney disease (CKD) and receiving dialysis for at least 3 months prior to screening - Baseline Hb level greater than or equal to 10.0 g/dL and less than or equal to 13.0 g/dL - Adequate iron stores (defined as serum ferritin greater than or equal to 100 µg/L or transferrin saturation \\[TSAT\\] greater than or equal to 20%) - Stable IV (epoetin alfa or beta) or SC rHuEPO (epoetin beta) therapy 2 or 3 times per week for at least 8 weeks before screening (stable is defined as less than 25% change in weekly dose and no change in frequency or route) - All subjects must practice adequate contraception (in the judgment of the investigator) throughout this trial"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "- Pregnant or breast-feeding women - Treatment with an investigational agent or device within 30 days before screening or scheduled to receive an investigational agent other than those specified by this protocol during the course of this study - Known sensitivity to any of the products to be administered during dosing - Disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "study procedures", "unit": null, "evidence_text": "- Pregnant or breast-feeding women - Treatment with an investigational agent or device within 30 days before screening or scheduled to receive an investigational agent other than those specified by this protocol during the course of this study - Known sensitivity to any of the products to be administered during dosing - Disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "pregnancy", "unit": null, "evidence_text": "- Pregnant or breast-feeding women - Treatment with an investigational agent or device within 30 days before screening or scheduled to receive an investigational agent other than those specified by this protocol during the course of this study - Known sensitivity to any of the products to be administered during dosing - Disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures"}]}
{"nct_id": "NCT00123799", "eligibility_text": "Inclusion Criteria:. * Male or female. If female of child bearing potential and outside of the window of 10 days since the last menstrual period, a negative pregnancy test.. * Biopsy proven breast carcinoma (core biopsy or fine needle aspiration, although core biopsies are preferred.). * Tumour size T1-3, N0 clinically. * All patients will have pre-operative mammography +/- ultrasound of the breast. * Age equal to or greater than 18 years. * Able and willing to follow instructions and comply with the protocol. * Provide written informed consent prior to participation in this study. Exclusion Criteria:. * Nursing or pregnant females. * Previous malignancy or diagnosis less than 10 (ten) years ago. Skin cancers (excluding malignant melanoma) and carcinoma in situ of the cervix are exceptions.. * Excisional biopsy of the tumour has been performed. * Age less than 18 years. * Patient has diabetes", "labeled_rules": [{"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Male or female"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "If female of child bearing potential and outside of the window of 10 days since the last menstrual period, a negative pregnancy test"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "the protocol", "unit": null, "evidence_text": "* Able and willing to follow instructions and comply with the protocol"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "pregnancy", "unit": null, "evidence_text": "* Nursing or pregnant females"}]}
{"nct_id": "NCT00128297", "eligibility_text": "Inclusion Criteria:. * Written informed consent.. * Up to two previous or current hormone therapy treatments for metastatic breast cancer are allowed.. * Normal or borderline renal function (serum creatinine \\< 1.5 x upper normal limit \\[UNL\\]).. * Normal calcium levels in serum, or slightly non-symptomatic high levels (\\< 1.25 x UNL).. * Performance status 0, I or II in World Health Organization (WHO) scale.. Exclusion Criteria:. * Treatment with bisphosphonates in the 30 previous days, or any time if the indication was treatment of metastatic bone lesions.. * Treatment with bisphosphonates is only allowed if the indication is hypercalcaemia.. * Metastases in central nervous system (CNS).. * Hypersensitivity to bisphosphonates or other components of the formula.. * Pregnant or lactating women.. * Previous or current treatment with a second chemotherapy line or a third hormone therapy line for metastatic disease.", "labeled_rules": [{"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Pregnant or lactating women"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "bisphosphonates is only allowed if the", "unit": null, "evidence_text": "* Treatment with bisphosphonates is only allowed if the indication is hypercalcaemia"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "a second chemotherapy line or a", "unit": null, "evidence_text": "* Previous or current treatment with a second chemotherapy line or a third hormone therapy line for metastatic disease"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "pregnancy", "unit": null, "evidence_text": "* Pregnant or lactating women"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "breastfeeding", "unit": null, "evidence_text": "* Pregnant or lactating women"}]}
{"nct_id": "NCT00129701", "eligibility_text": "Inclusion Criteria:. Patients who had already attended a respiratory clinic on at least two occasions and in whom it was perceived that there was a need for continued follow up in a hospital clinic with review needed more often than once per year Patients with no need for physical examinations or investigations such as chest X-rays, blood tests or lung function tests at every attendance Patients who had access to a confidential telephone line Patients who had no mental, hearing or linguistic problems. Exclusion criteria. New patients or those who need frequent follow up Patients with mental or cognitive issues Patients requiring physical examination and testing.", "labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "mental or cognitive issues requiring physical", "unit": null, "evidence_text": "New patients or those who need frequent follow up Patients with mental or cognitive issues Patients requiring physical examination and testing"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "follow up in a hospital clinic", "unit": null, "evidence_text": "Patients who had already attended a respiratory clinic on at least two occasions and in whom it was perceived that there was a need for continued follow up in a hospital clinic with review needed more often than once per year Patients with no need for physical examinations or investigations such as chest X-rays, blood tests or lung function tests at every attendance Patients who had access to a confidential telephone line Patients who had no mental, hearing or linguistic problems"}]}
{"nct_id": "NCT00134797", "eligibility_text": "Inclusion Criteria:. * All patients in the Internal Medicine Clinic at Naval Medical Center, San Diego (NMCSD) who were sent to the lab to obtain follow up by their primary care providers.. Exclusion Criteria:. * All patients referred to or being followed by nephrologists.", "labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "study-specific condition", "unit": null, "evidence_text": "Inclusion Criteria:"}, {"type": "INCLUSION", "field": "history", "operator": "EXISTS", "value": "manual review needed", "unit": null, "evidence_text": "* All patients in the Internal Medicine Clinic at Naval Medical Center, San Diego (NMCSD) who were sent to the lab to obtain follow up by their primary care providers"}]}
{"nct_id": "NCT00145158", "eligibility_text": "Inclusion Criteria. 1. Histologically proven cutaneous melanoma, or clear cell sarcoma, which is considered as a subtype of melanoma.. 2. Melanoma must be at one of the following AJCC 2002 stages:. * Regional metastatic disease (any T; N2b, N2c or N3; M0).. * Distant metastatic disease (any T; any N; M1a, M1b or M1c), except brain or leptomeningeal localizations, and except elevated LDH.. 3. Patients must be HLA-A2.. 4. A pre-immune tumor biopsy must be kept frozen for post-study PCR analysis.. 5. Presence of at least one measurable or non-measurable tumor lesion.. 6. Expected survival of at least 3 months.. 7. Karnofsky performance scale ≥70 or WHO performance status of 0 or 1.. 8. Within the last 4 weeks prior to study day 1, vital laboratory parameters should be within normal range, except for the following laboratory parameters, which must be within the ranges specified:. Lab Parameter Range. * Hemoglobin ≥ 10 g/dl or ≥ 6,25 mmol/l. * Granulocytes ≥ 1,500/µl. * Lymphocytes ≥ 700/µl. * Platelets ≥ 100,000/µl. * Serum creatinine ≤ 2.0 mg/dl or ≤ 177 μmol/l. * Serum bilirubin ≤ 2.0 mg/dl or ≤ 34.2 μmol/l. * ASAT and ALAT ≤ 2 x the normal upper limits. * LDH ≤ the normal upper limit.. 9. Viral tests:. * HIV (human immunodeficiency virus): negative antibodies.. * HBV (hepatitis B virus): negative antigens; antibodies may be positive.. * HCV (hepatitis C virus): negative antibodies.. 10. Age ≥ 18 years.. 11. Able and willing to give valid written informed consent.. Exclusion Criteria. 1. Previous treatment with more than one regimen of systemic chemotherapy, combined or not with non-specific immunotherapy such as interferon alpha or interleukins. Chemoimmunotherapy or radiotherapy must be stopped within the preceding 4 weeks (6 weeks for nitrosoureas and mitomycin C).. 2. Clinically significant heart disease (NYHA Class III or IV) i.e. NYHA class 3 congestive heart failure; myocardial infarction within the past six months; unstable angina; coronary angioplasty within the past 6 months; uncontrolled atrial or ventricular cardiac arrhythmias.. 3. Active immunodeficiency or autoimmune disease. Vitiligo was not an exclusion criterion.. 4. Other serious acute or chronic illnesses, e.g. active infections requiring antibiotics, bleeding disorders, or other conditions requiring concurrent medications not allowed during this study.. 5. Other malignancy within 3 years prior to entry into the study, except for treated non-melanoma skin cancer and cervical carcinoma in situ.. 6. Lack of availability for immunological and clinical follow-up assessments.. 7. Participation in any other clinical trial involving another investigational agent within 4 weeks prior to enrollment.. 8. Pregnancy or breastfeeding.. 9. Women of childbearing potential: Refusal or inability to use effective means of contraception.", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 3, "unit": "years", "evidence_text": "Expected survival of at least 3 months"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "Women of childbearing potential: Refusal or inability to use effective means of contraception"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "active infection", "unit": null, "evidence_text": "active infections requiring antibiotics, bleeding disorders, or other conditions requiring concurrent medications not allowed during this study"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "non-specific immunotherapy such as interferon alpha", "unit": null, "evidence_text": "Previous treatment with more than one regimen of systemic chemotherapy, combined or not with non-specific immunotherapy such as interferon alpha or interleukins"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "pregnancy", "unit": null, "evidence_text": "Pregnancy or breastfeeding"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "breastfeeding", "unit": null, "evidence_text": "Pregnancy or breastfeeding"}, {"type": "INCLUSION", "field": "history", "operator": "WITHIN_LAST", "value": 4, "unit": "weeks", "evidence_text": "Within the last 4 weeks prior to study day 1, vital laboratory parameters should be within normal range, except for the following laboratory parameters, which must be within the ranges specified:"}]}
{"nct_id": "NCT00151892", "eligibility_text": "Inclusion Criteria:. * previous diagnosis of ulcerative colitis confirmed by histology that has been considered to be in remission for =\\> 30 days. * female subjects must be post-menopausal, surgically or biologically sterile, or with a negative urine pregnancy test at screening and on adequate contraception. Exclusion Criteria:. * proctitis. * previous resective colonic surgery. * Crohn's disease. * hypersensitivity to salicylates. * moderate/severe renal impairment", "labeled_rules": [{"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* female subjects must be post-menopausal, surgically or biologically sterile, or with a negative urine pregnancy test at screening and on adequate contraception"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "a negative urine pregnancy test at", "unit": null, "evidence_text": "* female subjects must be post-menopausal, surgically or biologically sterile, or with a negative urine pregnancy test at screening and on adequate contraception"}]}
{"nct_id": "NCT00153569", "eligibility_text": "Inclusion Criteria:. * Metastatic melanoma. * HLA-A1, -A2, -A24, -B44. Exclusion Criteria:", "labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "study-specific condition", "unit": null, "evidence_text": "Inclusion Criteria:"}, {"type": "INCLUSION", "field": "history", "operator": "EXISTS", "value": "manual review needed", "unit": null, "evidence_text": "* Metastatic melanoma"}]}
{"nct_id": "NCT00156507", "eligibility_text": "Inclusion Criteria:. * Premature babies weighing less than 1500 grams at birth receiving care at Strong Memorial Hospital Neonatal Intensive Care Unit. Exclusion Criteria:. * Non-English speaking parents", "labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "study-specific condition", "unit": null, "evidence_text": "Inclusion Criteria:"}, {"type": "INCLUSION", "field": "history", "operator": "EXISTS", "value": "manual review needed", "unit": null, "evidence_text": "* Premature babies weighing less than 1500 grams at birth receiving care at Strong Memorial Hospital Neonatal Intensive Care Unit"}]}
{"nct_id": "NCT00158002", "eligibility_text": "Inclusion Criteria:. * Must have either completed the Double-Blind Phase of CAPSS-271 or discontinued the Double-Blind Phase of CAPSS-271 due to lack of efficacy after a minimum of 2 weeks of maintenance treatment.. * Must continue to meet the specific inclusion criteria outlined in CAPSS-271.. * Female subjects must be premenarchal, surgically sterile (hysterectomy, tubal ligation or otherwise incapable of pregnancy); or practicing an effective method of birth control (e.g., intrauterine device, double-barrier method, male partner sterilization) at study entry and throughout the study; or hormonal contraceptives for at least a 3-month period prior to the start of the study and throughout the study, or be practicing abstinence and agree to continue abstinence or to use an acceptable method of contraception (as listed above) should sexual activity commence. In addition, female subjects of childbearing potential must have a negative urine pregnancy test at Open-Label Visit 1 (Day 1).. * Must be able to read and comprehend written instructions and be willing to complete all headache records and questionnaires as required by the protocol.. * After full explanation of the study, subjects, or their parent/legally authorized representative(s), must demonstrate their willingness to participate by signing an informed consent form. If applicable, pediatric subjects capable of giving assent must sign the assent form.. Exclusion Criteria:. * Subjects who have developed a more painful condition than their headache pain.. * Subjects taking any of the prohibited concomitant medications (See Concomitant Medications section).. * Subjects who are pregnant.. * Subjects with liver function tests ³ 2 times the upper limit of the normal range.. * In the investigator's opinion, subjects with poor compliance during the CAPSS-271 study", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 2, "unit": "years", "evidence_text": "* Must have either completed the Double-Blind Phase of CAPSS-271 or discontinued the Double-Blind Phase of CAPSS-271 due to lack of efficacy after a minimum of 2 weeks of maintenance treatment"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Female subjects must be premenarchal, surgically sterile (hysterectomy, tubal ligation or otherwise incapable of pregnancy)"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "In addition, female subjects of childbearing potential must have a negative urine pregnancy test at Open-Label Visit 1 (Day 1)"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "or practicing an effective method of birth control (e.g., intrauterine device, double-barrier method, male partner sterilization) at study entry and throughout the study"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "poor compliance during the capss-271 study", "unit": null, "evidence_text": "* In the investigator's opinion, subjects with poor compliance during the CAPSS-271 study"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "pregnancy", "unit": null, "evidence_text": "* Subjects who are pregnant"}]}
{"nct_id": "NCT00159380", "eligibility_text": "Inclusion Criteria:. Healthy non-smokers (n=10):. * Nonatopic subjects (exhaled NO greater than or equal to 10 ppb; flow 50 ml/s). * Normal spirometry. * Able to comprehend and grant a written informed consent. Asthmatic subjects (n=15):. * Forced expiratory volume in one second (FEV1) of no less than 70% of predicted (exhaled NO greater than or equal to 15 ppb; flow 50 ml/s). * Clinically stable (steroid-naïve or taking no \\> 600 mcg/day of inhaled steroids). * Able to comprehend and grant a written informed consent. Exclusion Criteria:. * Currently smoking. * Any lung disease other than asthma which may interfere with the study. * Treatment within the last 4 weeks with oral steroids. * Respiratory infection within 4 weeks prior to entry into the trial. * Females who are pregnant or lactating. * History of current or past drug or alcohol abuse", "labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "current or past drug or alcohol", "unit": null, "evidence_text": "* History of current or past drug or alcohol abuse"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "oral steroids", "unit": null, "evidence_text": "* Treatment within the last 4 weeks with oral steroids"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "the study", "unit": null, "evidence_text": "* Any lung disease other than asthma which may interfere with the study"}, {"type": "EXCLUSION", "field": "medication", "operator": "WITHIN_LAST", "value": 4, "unit": "weeks", "evidence_text": "* Treatment within the last 4 weeks with oral steroids"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "pregnancy", "unit": null, "evidence_text": "* Females who are pregnant or lactating"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "breastfeeding", "unit": null, "evidence_text": "* Females who are pregnant or lactating"}]}
{"nct_id": "NCT00159458", "eligibility_text": "Inclusion Criteria:. * Histologically proven dx of recurrent or metastatic breast cancer. * Must have received at least 1 but not more than 3 prior chemotherapy regimens for recurrent or metastatic breast cancer. Patients who relapse within 12 months of completing adjuvant chemotherapy can only have had up to 2 prior regimens for metastatic disease. Patients who relapse within 12 months of completing adjuvant chemotherapy containing an anthracycline and a taxane, do not require prior chemotherapy for metastatic disease.. * Unidimensionally measurable dz (by RECIST). * At least 18 yrs of age. * SWOG PS 0-2. * AGC greater than or equal to 1.5; platelets greater than or equal to 100,000; Hgb greater than or equal to 8.0. * Total bilirubin less than or equal to 2 x uln; SGOT and/or SGPT and alk phos up to 2.5 x uln. * Creatinine less than or equal to 2.0. * Fully recovered from acute toxicities secondary to prior tx. * Signed informed consent (including HIPAA authorization). * Peripheral neuropathy grade 0-1. Exclusion Criteria. * Prior tx with gemcitabine or oxaliplatin. Prior tx with cisplatin or carboplatin allowed if completed \\>12 mos prior to enrollment.. * Underlying medical, psychiatric, or social conditions that would preclude patient from receiving tx. * Peripheral neuropathy greater than or equal to Gr 2. Exclusion Criteria:. \\-", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "* At least 18 yrs of age"}, {"type": "INCLUSION", "field": "age", "operator": "<=", "value": 2, "unit": "years", "evidence_text": "SGOT and/or SGPT and alk phos up to 2.5 x uln"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 1, "unit": "years", "evidence_text": "* Must have received at least 1 but not more than 3 prior chemotherapy regimens for recurrent or metastatic breast cancer"}, {"type": "INCLUSION", "field": "age", "operator": "<=", "value": 2, "unit": "years", "evidence_text": "Patients who relapse within 12 months of completing adjuvant chemotherapy can only have had up to 2 prior regimens for metastatic disease"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "gemcitabine or oxaliplatin", "unit": null, "evidence_text": "* Prior tx with gemcitabine or oxaliplatin"}]}
{"nct_id": "NCT00162305", "eligibility_text": "Inclusion Criteria:. * Established diagnosis of Type 2 diabetes mellitus, who are treated with metformin or diet alone (drug naive).. * Fasting glucose (FG) \\< - 240 mg/dL, while on metformin or antidiabetic diet alone.. * HbA1c (Hemoglobin A1c) in the range of 6.0-10.0%. Exclusion Criteria:. * Women of childbearing potential", "labeled_rules": [{"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Women of childbearing potential"}, {"type": "INCLUSION", "field": "history", "operator": "EXISTS", "value": "manual review needed", "unit": null, "evidence_text": "* Established diagnosis of Type 2 diabetes mellitus, who are treated with metformin or diet alone (drug naive)"}]}
{"nct_id": "NCT00181272", "eligibility_text": "Inclusion Criteria:. * Physician-diagnosis of asthma, COPD exacerbation, or undifferentiated asthma/COPD exacerbation. * Admitted to the inpatient medical service at Johns Hopkins Hospital or Johns Hopkins Bayview Medical Center. * Evidence of airflow obstruction on spirometry (FEV1/FVC\\<70%). * Age 18 years or older. Exclusion Criteria:. * History of allergy or other contraindication to macrolides (azithromycin, erythromycin, clarithromycin). * Treatment with any macrolide in the 4 weeks prior to study entry. * Elevated AST or ALT (2 or more times the upper limit of normal) on current admission. * Elevated alkaline phosphatase (\\>1.25 times the upper limit of normal) on current admission. * Elevated total serum bilirubin (more than upper limit of normal) on current admission. * Previous participation in this study. * Patients prescribed digoxin (azithromycin may increase digoxin levels). * Patients prescribed warfarin (azithromycin may increase INR in patients on warfarin). * Patients prescribed pimozide (azithromycin may increase risk of arrhythmias). * Patient unable to provide consent (e.g., language difficulty or history of dementia). * Patient to be discharged to a location other than home (e.g., other hospital, long-term care facility)", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "* Age 18 years or older"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "any macrolide in the 4 weeks", "unit": null, "evidence_text": "* Treatment with any macrolide in the 4 weeks prior to study entry"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "azithromycin may increase inr in", "unit": null, "evidence_text": "* Patients prescribed warfarin (azithromycin may increase INR in patients on warfarin)"}]}
{"nct_id": "NCT00184288", "eligibility_text": "Inclusion Criteria:. * Clinical diagnosis of brain metastases. Exclusion Criteria:. * children. * pregnancy", "labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "brain metastases", "unit": null, "evidence_text": "* Clinical diagnosis of brain metastases"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "pregnancy", "unit": null, "evidence_text": "* pregnancy"}]}
{"nct_id": "NCT00189332", "eligibility_text": "Inclusion Criteria:. * Advanced melanoma not responding to 1st line chemotherapy. * Histological evidence of melanoma. * Measurable disease according to RECIST criteria. * ECOG performance status less than or equal to 2. * Life expectancy 6 months or more. * Normal organ and bone marrow function as defined by hematological and serum chemistry limits. * Adequate contraception for females of childbearing potential. Exclusion Criteria:. * Stage IV disease which has previously progressed during interferon treatment.. * Restriction of some therapies/medications for a certain timeframe prior to enrollment and during the study including: investigational drugs, high dose corticosteroids, immunotherapy, immunosuppressive medications, radiotherapy and drugs known to prolong QT interval and/or induce Torsades De Pointes. * History of uncontrolled seizure disorders. * Uncontrolled coagulation disorders.. * History or evidence of myocardial ischemia, congestive heart failure or arrythmias requiring treatment in the past 6 months. * History of uncontrolled intercurrent or chronic illness. * Concurrent malignancies.. * Brain metastases.. * HIV positive.. * Prolonged QTc interval. * Uncontrolled intercurrent or chronic illnesses.. * Pregnant or lactating women", "labeled_rules": [{"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Pregnant or lactating women"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hiv positive", "unit": null, "evidence_text": "* HIV positive"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "uncontrolled seizure disorders", "unit": null, "evidence_text": "* History of uncontrolled seizure disorders"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "uncontrolled intercurrent or chronic illness", "unit": null, "evidence_text": "* History of uncontrolled intercurrent or chronic illness"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "pregnancy", "unit": null, "evidence_text": "* Pregnant or lactating women"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "breastfeeding", "unit": null, "evidence_text": "* Pregnant or lactating women"}]}
{"nct_id": "NCT00207038", "eligibility_text": "Inclusion Criteria:. * Swimmer. Exclusion Criteria:. * Current smoker or more than 3 pack-years", "labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "study-specific condition", "unit": null, "evidence_text": "Inclusion Criteria:"}, {"type": "INCLUSION", "field": "history", "operator": "EXISTS", "value": "manual review needed", "unit": null, "evidence_text": "* Swimmer"}]}
{"nct_id": "NCT00232726", "eligibility_text": "Inclusion Criteria:. * Patients with histologically or cytologically confirmed stage IV or unresectable stage III non-ocular malignant melanoma who have not undergone prior chemotherapy for the treatment of melanoma (chemotherapy-naïve). * Measurable disease according to Response Criteria in Solid Tumours (RECIST). * Performance Status 0 - 2 according to ECOG (Eastern Cooperative Oncology Group) Performance Status. * Age 18 years or more. * Life expectancy \\> 3 months. * Signed informed consent. * Adequate haematological and biological functions:. * Bone marrow function:. 1. Neutrophils ≥ 1.5 x 10\\^9/L. 2. Platelets ≥ 100 x 10\\^9/L. 3. Hemoglobin (Hb) ≥ 10 g/dL. * Hepatic function:. 1. AST/ALT ≤ 2.5 times institutional upper limit of normal (ULN). If liver metastases, ≤ 5 times institutional ULN.. 2. Serum bilirubin and alkaline phosphatase ≤ 1.5 times institutional ULN. * Renal function:. * Creatinine ≤ 1.5 times institutional ULN. Exclusion Criteria:. * Known brain metastases. * Diagnosis of ocular malignant melanoma. * Radiotherapy to more than 30% of bone marrow. * Participation in another therapeutic clinical study within 30 days of enrolment or during this clinical study. * Prior immunotherapy and/or chemotherapy for the treatment of melanoma. * Requirement of concomitant treatment with a non-permitted medication:. * Alternative drugs. * High doses of vitamins. * History of allergic reactions to Ara-C or egg. * Presence of any serious concomitant systemic disorders incompatible with the clinical study (e.g. uncontrolled intercurrent illness including ongoing or active infection). * Presence of any significant central nervous system or psychiatric disorder(s) that would hamper the patient's compliance. * Pregnancy, breastfeeding, or absence of adequate contraception for both male and female fertile patients. * Known positive status for HIV and/or hepatitis B or C. * Drug and/or alcohol abuse. * Any reason why, in the Investigator's opinion, the patient should not participate", "labeled_rules": [{"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Pregnancy, breastfeeding, or absence of adequate contraception for both male and female fertile patients"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "ocular malignant melanoma", "unit": null, "evidence_text": "* Diagnosis of ocular malignant melanoma"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "allergic reactions to ara-c or egg", "unit": null, "evidence_text": "* History of allergic reactions to Ara-C or egg"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hiv positive", "unit": null, "evidence_text": "* Known positive status for HIV and/or hepatitis B or C"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "active infection", "unit": null, "evidence_text": "uncontrolled intercurrent illness including ongoing or active infection)"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "or absence of adequate contraception for", "unit": null, "evidence_text": "* Pregnancy, breastfeeding, or absence of adequate contraception for both male and female fertile patients"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "pregnancy", "unit": null, "evidence_text": "* Pregnancy, breastfeeding, or absence of adequate contraception for both male and female fertile patients"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "breastfeeding", "unit": null, "evidence_text": "* Pregnancy, breastfeeding, or absence of adequate contraception for both male and female fertile patients"}]}
{"nct_id": "NCT00235859", "eligibility_text": "Inclusion Criteria:. * Meet ACR criteria for diagnosis of active RA and have at \\>6 swollen joints and \\>9 tender joints. * Subjects must have received at least one prior DMARD besides MTX, but may have had efficacy failures on no more than four standard DMARDs other than MTX. * Therapy with MTX for at least 6 months prior to screening and on a stable dose of MTX for at least 4 weeks prior to screening visit. * Age 18 years and older. Exclusion Criteria:. * Prior treatment with any TNF antagonist, including adalimumab. * History of clinically significant drug or alcohol abuse in the previous year, iv drug abuse, active infection with listeria or tuberculosis (TB), lymphoma or leukemia,and any malignancy with the exception of successfully treated non-metastatic basal-cell carcinoma of the skin.. * Subjects may not have been administered a live vaccine within three months prior to study drug administration or during the study, treatment with any other investigational agent within 30 days or 5 half-lives of the agent, whichever is longer, prior to the screening evaluation, treatment with any investigational biologic agent, including anti-CD4 antibody, within 6 months prior to the screening evaluation, prior treatment with any TNF antagonist, including Adalimumab, prior exposure to alkylating agents such as chlorambucil or cyclophosphamide.. * Chest X-ray with calcified granuloma and/or pleural scarring. * Positive TB skin test, RT23 dose skin test, \\>5 mm at 48 to 72 hours. * Unstable ischemic heart disease, active inflammatory bowel disease, active peptic ulcer disease, recent stroke (within 3 months of the screening evaluation) or any poorly controlled medical condition. * Intra-articular, intramuscular or iv administration of corticosteroids within 4 weeks prior to screening evaluation. * Female who is pregnant or breast-feeding.", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "* Age 18 years and older"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 6, "unit": "years", "evidence_text": "* Therapy with MTX for at least 6 months prior to screening and on a stable dose of MTX for at least 4 weeks prior to screening visit"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Female who is pregnant or breast-feeding"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "any tnf antagonist, including adalimumab", "unit": null, "evidence_text": "* Prior treatment with any TNF antagonist, including adalimumab"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "active infection", "unit": null, "evidence_text": "* History of clinically significant drug or alcohol abuse in the previous year, iv drug abuse, active infection with listeria or tuberculosis (TB), lymphoma or leukemia,and any malignancy with the exception of successfully treated non-metastatic basal-cell carcinoma of the skin"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "pregnancy", "unit": null, "evidence_text": "* Female who is pregnant or breast-feeding"}]}
{"nct_id": "NCT00238069", "eligibility_text": "Inclusion Criteria:. * Adult (\\>18yrs at the time of recruitment). * Body mass index (BMI) ≥ 30. * Symptoms suggestive of sleep apnea. * Epworth Sleepiness Score (ESS) within range. * Positive sleep study for sleep apnea. Exclusion Criteria:. * Tobacco use within the last 3 months.. * Presence of other significant comorbid heart or lung disease. * Presence of another chronic inflammatory disease, such as connective-tissue disease, inflammatory bowel disease, or active infection.. * Use of systemic steroids, as defined as any prednisone use in the preceding 3 months.. * Use of leukotriene antagonists or theophylline within the preceding 6 weeks.. * Presence of severe or uncontrolled sinusitis, such that CPAP therapy will be difficult or uncomfortable.. * History of significant claustrophobia, uncontrolled psychiatric disease, or anticipated intolerance of CPAP therapy.. * Night shift workers, or other subjects with significantly altered sleep-wake cycles.. * Baseline post-bronchodilator FEV1 \\< 70% predicted.. * Severe gastroesophageal reflux disease.", "labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "significantly altered sleep-wake cycles", "unit": null, "evidence_text": "* Night shift workers, or other subjects with significantly altered sleep-wake cycles"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "active infection", "unit": null, "evidence_text": "* Presence of another chronic inflammatory disease, such as connective-tissue disease, inflammatory bowel disease, or active infection"}, {"type": "EXCLUSION", "field": "history", "operator": "WITHIN_LAST", "value": 3, "unit": "months", "evidence_text": "* Tobacco use within the last 3 months"}]}
{"nct_id": "NCT00250445", "eligibility_text": "Inclusion Criteria:. * Patient has a clinical diagnosis of either Osteoarthritis or Rheumatoid Arthritis and in the opinion of the investigator will require chronic nonsteroidal anti-inflammatory or COX-2 inhibitor therapy for at least 1.5 years. Exclusion Criteria:. * Concurrent medical or arthritic disease that could confound or interfere with efficacy evaluation.. * Concomitant therapy of warfarin, heparin, high-dose aspirin (\\>100 mg/day).. * Impaired kidney function, clinical gastrointestinal malabsorption, congestive heart failure with symptoms that occur at rest, unstable angina, uncontrolled high blood pressure, active hepatitis/hepatic disease", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 1, "unit": "years", "evidence_text": "* Patient has a clinical diagnosis of either Osteoarthritis or Rheumatoid Arthritis and in the opinion of the investigator will require chronic nonsteroidal anti-inflammatory or COX-2 inhibitor therapy for at least 1.5 years"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "efficacy evaluation", "unit": null, "evidence_text": "* Concurrent medical or arthritic disease that could confound or interfere with efficacy evaluation"}]}
{"nct_id": "NCT00257283", "eligibility_text": "Inclusion Criteria:. * Males and females above 18 years of age. * Patients having been treated with chronic hemodialysis for at least 6 months. * Patients with documented cardiovascular disease, at least one of the following. 1. Angina pectoris. 2. Previous Acute myocardial infarction. 3. Previous PTCA/CABG or demonstated atheroclerosis after coronary angio. 4. Previous Transitory Cerebral Ischemia. 5. Previous Apoplexia Cerebri. 6. Symptoms of peripheral vascular disease. * Written informed consent. Exclusion Criteria:. * Active malignant disease, except basal cell carcinoma or spinocellular carcinoma. * Patients undergoing peritoneal dialysis. * Any condition associated with a risk of poor compliance, as judged by investigator. * Pregnant or breastfeeding. * Participation in other clinical studies involving treatment with drugs.", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 6, "unit": "years", "evidence_text": "* Patients having been treated with chronic hemodialysis for at least 6 months"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "drugs", "unit": null, "evidence_text": "* Participation in other clinical studies involving treatment with drugs"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "a risk of poor compliance, as", "unit": null, "evidence_text": "* Any condition associated with a risk of poor compliance, as judged by investigator"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "chronic hemodialysis for at least 6", "unit": null, "evidence_text": "* Patients having been treated with chronic hemodialysis for at least 6 months"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "documented cardiovascular disease, at least one", "unit": null, "evidence_text": "* Patients with documented cardiovascular disease, at least one of the following"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "pregnancy", "unit": null, "evidence_text": "* Pregnant or breastfeeding"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "breastfeeding", "unit": null, "evidence_text": "* Pregnant or breastfeeding"}]}
